Huiling Han (MD) is the R&D Director at ILS. She has been working for ILS for more than 10 years, and her research in hybridoma cell lines and polyclonal antibodies led to the launch of all commercial ELSA kits and CLIA tests at ILS. She also serves as the leading scientist in ILS’s NIH SBIR Phase I, II, IIB studies and commercial services for special RUO assays for ILS’s pharmaceutical investigators worldwide.
Before joining ILS, she was a scientist and research fellow in both academic and industrial research settings. In addition to a ten year tenure at the University of California San Diego Cancer Center and Hybridoma core facility, she spent time at Novasite Pharmaceuticals and Genlantis Inc. Huiling brings a diverse set of skills in molecular biology, biochemistry, cell biology, glycobiology, cancer and vascular biology, and immunology, as well as commercialization of biochemicals and pharmaceuticals. She also holds multiple patents and MD from Fudan University School of Medicine in Shanghai, China, a top 5 university in China.